This is a two-year double blind, placebo-controlled, and randomized clinical trial, which is aimed to evaluate the effects of Chinese medical treatment on leucopenia after chemotherapy in breast cancer patients.
The study will be conducted in the Department of Breast Surgery in China Medical University Hospital, Taichung. One hundred newly diagnosed breast cancer patient (age ≧18, Stage I, II, IIIa) will be included. After the diagnosis, the patients will undergo operation. Then, each patient will receive one of the following protocol of chemotherapy according to her pathology report and overall evaluation: "FEC\*6", "FEC\*4+Taxotere\*4", and "FEC\*3+Taxotere\*3". Every participator will start to take the powder of Chinese herb-LCH1 after her receiving first time of chemotherapy until she receives the next cycle.(While receiving "FEC", it will be 3 weeks. While receiving "Taxotere", it will be 4 weeks). Just before receiving the next cycle of chemotherapy, the blood of the participator will be sampled to check her CBC, GOT/GPT, BUN/Cr and tumor maker. The investigators also adopt the body constitution questionnaire (BCQ) to evaluate the Chinese medical constitutional status, the EORTC QLQ-C30, EORTC QLQ-BR23, and Karnofsky score to evaluate the quality of life, and to evaluate the adverse effects of the adjuvant chemotherapy with the NCI-CTCAE Version 3.0. Each participator will take the powder of Chinese herb-LCH1 from her first chemotherapy till 3 weeks after the last cycle of chemotherapy. Over all, it will take about 18 weeks (FEC\*6) to 28 weeks (FEC\*4+Taxotere\*4) to complete the treatment. This study will also investigate the influence of the chemotherapy on the Chinese medical constitutional status, and in order to provide the basis for the complementary treatment for the breast cancer by adjusting and balancing the constitutional status of the patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
100
Start to take the powder of Chinese herb-LCH1 3g\*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
Start to take the powder of Placebo 3g\*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
Devision of Breast Surgery, China Medical University Hospital
Taichung, Taiwan, Taiwan
ENROLLING_BY_INVITATIONDevision of Breast Surgery, China Medical University Hospital
Taichung, Taiwan, Taiwan
RECRUITINGDivision of General surgery, Tri-Service General Hospital
Taipei, Taiwan, Taiwan
ENROLLING_BY_INVITATIONWBC Count
All the patients will be stratified according to her chemotherapy protocol : "FEC\*6", "FEC\*4+Taxotere\*4", and "FEC\*3+Taxotere\*3". The WBC will be checked before receiving each cycle of chemotherapy and at the follow up 3 weeks after the completion of chemotherapy. If the participator receives the protocol "FEC\*6", her WBC will be checked every 3 weeks for 7 times. It will takes 21 weeks to get the values of WBC at 7 different time point. And it will takes 31 weeks and 24 weeks for participators receive the protocol "FEC\*4+Taxotere\*4" and "FEC\*3+Taxotere\*3", respectively.
Time frame: 21-31 weeks, which depands on the patients' chemotherapy protocol.
Score of EORTC QLQ-C30
All the patients will be stratified according to her chemotherapy protocol : "FEC\*6", "FEC\*4+Taxotere\*4", and "FEC\*3+Taxotere\*3". Score of EORTC QLQ-C30 will be evaluated before receiving each cycle of chemotherapy and at the follow up 3 weeks after the completion of chemotherapy. If the participator receives the protocol "FEC\*6", her score will be checked every 3 weeks for 7 times. It will takes 21 weeks to get the score at 7 different time point. And it will takes 31 weeks and 24 weeks for participators receive the protocol "FEC\*4+Taxotere\*4" and "FEC\*3+Taxotere\*3", respectively.
Time frame: 21-31 weeks, which depands on the patients' chemotherapy protocol.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.